return to news
  1. Antimicrobial drugs to face tighter checks; govt proposes central approval for manufacturing

Business News

Antimicrobial drugs to face tighter checks; govt proposes central approval for manufacturing

Upstox

2 min read | Updated on November 19, 2026, 13:44 IST

SUMMARY

The proposed changes are expected to address gaps in regulatory scrutiny, including the absence of mandatory bioavailability/bioequivalence and stability assessments, which could compromise drug quality, safety and efficacy.

antimicrobial drugs

Manufacturers would need prior permission from the Central Licensing Authority before applying for manufacturing licences from state authorities. Image: Shutterstock

The Union Health Ministry has proposed bringing antimicrobial drugs under the central regulatory framework for new drugs to strengthen quality checks and tackle the growing threat of antimicrobial resistance (AMR).

Open FREE Demat Account within minutes!
Join now

The draft notification proposes inserting the word “antimicrobials” after “monoclonal anti-body” in the relevant provision of the 2019 rules.

Under the proposed changes, manufacturers of antimicrobial products will have to obtain prior permission from the Central Licensing Authority (CLA) before applying for a manufacturing licence from the respective State Licensing Authority (SLA).

The move follows concerns over manufacturing licences being granted for antimicrobial products without adequate regulatory scrutiny, including mandatory assessments such as bioavailability/bioequivalence and stability studies.

The absence of such assessments could compromise the quality, safety and efficacy of antimicrobial products, the ministry said.

“Substandard or ineffective antimicrobials can contribute to the development and spread of antimicrobial resistance, posing risks to patient safety,” it said.

Antimicrobial resistance, which occurs when microorganisms develop the ability to withstand medicines designed to kill them, is a major global public health concern and requires coordinated action, the ministry said.

The G20 New Delhi Leaders’ Declaration had also underscored the need to address AMR through a One Health approach, which recognises the interconnectedness of human, animal and environmental health.

The proposed amendment is intended to bring antimicrobials within the regulatory framework applicable to new drugs under the 2019 rules and strengthen central oversight to ensure their quality, safety and efficacy.

The ministry has issued a draft notification inviting objections and suggestions from stakeholders and members of the public before finalising the proposed changes.

About The Author

Upstox
Upstox News Desk is a team of journalists who passionately cover stock markets, economy, commodities, latest business trends, and personal finance.

Next Story

End of additional stories